Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
Sign Up to like & getrecommendations! Published in 2021 at "Neoplasma"
DOI: 10.4149/neo_2021_200506n489
Abstract: Osimertinib (OSI) resistance commonly occurs during the treatment of non-small-cell lung cancer (NSCLC). This study aims to investigate whether the thermal effects of radiofrequency ablation (RFA) can increase the sensitivity of OSI-resistant NSCLC to OSI… read more here.
Keywords: treatment; h1975; h1975 osir; cell ... See more keywords